Will The Dark Tunnel For Korean Biopharmas End In 2023?

Eyes On Lung Cancer, Alzheimer’s Segment

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Man walk through crystal corridor
Korean Firms See Decline In Financing, Licensing Deals In 2022 • Source: Shutterstock

More from Business

More from Scrip